Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Osimertininb dosing · 1 trial · 1 indication
To characterize the pharmacokinetics of fexofenadine by assessment of maximum plasma fexofenadine concentration.
To characterize the pharmacokinetics of fexofenadine by assessment of area under the plasma concentration time curve from zero to infinity
| Arm | Type | Description |
|---|---|---|
| osimertinib and fexofenadine | EXPERIMENTAL | Sequential treatments of fexofenadine alone followed by osimertinib + fexofenadine, followed by osimertinib alone, followed by osimertinib + fexofenadine |
| Name | Type | Description |
|---|---|---|
| Fexofenadine tablet dosing | DRUG | Fexofenadine (P-gp substrate) 120mg taken once daily on Days 1 in Treatment Period 1 and Day 1 and Day 39 in Treatment Period 2 |
| Osimertininb tablet dosing | DRUG | Osimertininb 80 mg taken once daily on Day 1 and Days 4 to 41 in Treatment Period 2 |
Inclusion Criteria: * Male or female, ≥18 years * Histological or cytological confirmation diagnosis of NSCLC * Radiological documentation of disease progression while receiving previous continuous treatment with an EGFR-TKI. * Confirmation that the tumour harbours an EGFR mutation known to be asso...
Top 20 of 84 competitors
Osimertinib is a small molecule drug being studied for use in Non Small Cell Lung Cancer (NSCLC). It is an investigational therapy developed by AstraZeneca PLC (AZN). The drug is currently in Phase 1 clinical development, with one completed trial assessing its effects in patients with EGFRm+ NSCLC.
Osimertinib is developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The drug is being studied for the treatment of Non Small Cell Lung Cancer and is currently in Phase 1 clinical development.
Osimertinib is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is being studied for Non Small Cell Lung Cancer. One Phase 1 trial has been completed, with a total enrollment of 24 patients.
Osimertinib has one completed clinical trial, identified as NCT02908750, titled 'Study to Assess the Effect of Osimertinib (TAGRISSO™) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC'. This Phase 1 trial enrolled 24 patients with Non Small Cell Lung Cancer and was conducted in France, South Korea, and Spain.
Yes, Osimertinib is also known as TAGRISSO, as indicated in the clinical trial title. The drug is being developed by AstraZeneca PLC for Non Small Cell Lung Cancer and is currently in Phase 1 clinical development.